Bedrijfsoverzicht
Zai Lab Limited is a biopharmaceutical entity dedicated to the discovery, development, and commercialization of therapeutic products targeting medical conditions within oncology, immunology, neuroscience, and infectious diseases. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, an environment characterized by high research expenditures and the pursuit of novel biological treatments to address unmet medical needs. Zai Lab holds a market capitalization of $2.34B and reported annual revenue (TTM) of $460.16M, employing a workforce of 1784 individuals to support its extensive research and commercialization efforts. These financial figures indicate that the company has established a significant position within the biotechnology landscape, maintaining a substantial valuation despite its current stage of commercialization and operational scaling. The scale of its operations, reflected in a multi-billion dollar market cap, suggests confidence from the market regarding its proprietary pipeline and commercial potential, particularly with products like Zejula which is an orally administered poly (ADP-ribose) polymerase inhibitor for oncology.
Financiële gezondheid
The company reported revenue (TTM) of $460.16M, net income (TTM) of $-175,536,992, and EBITDA of $-214,424,000, revealing a substantial gap between top-line growth and bottom-line profitability driven by significant operating expenses. This negative net income relative to revenue highlights a cost structure typical of biotechnology firms in the growth phase, where heavy investment in research and development and commercialization activities outweighs immediate earnings generation. Free cash flow stands at $-92,507,872, indicating that the company is currently burning cash to fund its operations and pipeline development rather than generating surplus liquidity from its current business model. Despite this cash burn, the company maintains a cash balance of $689.57M against total debt of $224.26M, resulting in a debt-to-equity ratio of 31.34 which reflects a leveraged but manageable capital structure given the cash reserves. The current ratio of 2.45 demonstrates strong short-term liquidity, suggesting the company possesses ample current assets to cover its short-term liabilities without immediate distress. Furthermore, the return on equity is -22.6% and the return on assets is -12.2%, metrics that indicate the company is currently diluting shareholder value and utilizing assets to generate negative returns as it prioritizes long-term asset building over immediate profitability.
Waarderingsbeoordeling
Zai Lab's trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -14.81, a metric that implies the market prices the stock based on future anticipated earnings normalization rather than current historical performance. The price-to-book ratio is 3.20, indicating that the market values the company at more than three times its book value, which suggests a premium assigned to its intangible assets, intellectual property, and potential value of the drug pipeline. Alternative valuation metrics include a price-to-sales ratio of 5.08 and an EV/EBITDA of -104.54, figures that suggest the market is valuing the company primarily on its revenue generation capabilities and sales pipeline rather than current cash flow generation or earnings power. The stock has traded within a 52-week range between a low of $15.96 and a high of $44.34, with the current price position relative to this range reflecting recent market sentiment and volatility adjustments. The beta value of 0.86 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to high-beta technology or biotech stocks.
Growth & Income
Revenue growth year-over-year is 17.0%, while earnings growth is not available due to the company's current unprofitability, implying that top-line expansion is the primary driver of value creation at this stage rather than margin improvement. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning all earnings, including the negative ones, are effectively retained or utilized to fund operations rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology companies that must allocate capital to clinical trials and regulatory approvals to advance their products toward market approval and commercialization. The overall growth and income profile is defined by robust revenue expansion in the face of significant financial losses, with no income distribution to investors, focusing entirely on the potential future commercialization of its medical product portfolio.